KRAS- and BRAF-Mutations and their clinical correlates in a prospective, multi-center, diagnostic clinical trial „molecular signatures in colorectal cancer“ (MSKK)
P Pechanska, R Mantke, R Pauli, K Ridwelski, K Hellwig, M Pross, C Radke, B Unger, H Lobeck, J Pertschy, H Kosmehl, T Manger, C Boltze, T Buthut, V Henn, B Hinzmann, I Klaman, HP Adams, D Nürnberg, A Rosenthal · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: KRAS mutation status is already used for tailoring therapy in colorectal cancer patients. Therefore, we investigated the relation of KRAS- and BRAF-status (mutated or wild type (WT)) with patient and tumor characteristics in the framework of a multi-center prospective study (MSKK) aiming at development of predictive and prognostic biomarkers. Methods: We have analyzed KRAS- and BRAF-mutation status in macro-dissected paraffin-embedded and snap-frozen tumor samples from 581 patients (52% male; 48% female, age: 36yrs –93yrs (median 70yrs), UICC-stages: I 21.2%, II 32.9%, III 35.6%, IV 10.3%), tumor location:…
